DEVELOPMENTAL FUNDS ABSTRACT Developmental funds are used to shape and implement the vision of the Knight Cancer Institute. Controlled by the institute's director and derived from Knight philanthropic awards, OHSU institutional commitment, and support from the CCSG, these funds are critical to the Knight's strategic planning and success. During the past CCSG period, development funds helped the institute recruit 32 scientists. Investment of $1.18 million in pilot project funding between FY12-FY14 contributed to over $12.4 million of external funding. Development funds enabled the institute to expand multiple shared resources available to cancer researchers, including over $9 million in capital purchases for the Advance Multiscale Microscopy Shared Resource, $5.8 million in operating and capital equipment costs for the BioLibrary & Pathology Shared Resource, and $500,000 to facilitate the developing Knight Bioinformatics Shared Resource. With sharp trajectory of growth in the Knight, development funds will be used to support the recruitment of early detection researchers and clinician scientists and support ongoing excellence in each of the programs. We will continue to provide pilot project funding to facilitate inter-progammatic collaboration, and generation of prelimary data to support the development and submission of peer-reviewed funding applications. With the growth and expansion of the Knight, we anticipate developing new shared resources to support the scientifc needs of our investigators.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA069533-21
Application #
9733137
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-07-01
Budget End
2020-06-30
Support Year
21
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Oregon Health and Science University
Department
Type
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Hulett, Tyler W; Jensen, Shawn M; Wilmarth, Phillip A et al. (2018) Coordinated responses to individual tumor antigens by IgG antibody and CD8+ T cells following cancer vaccination. J Immunother Cancer 6:27
Vranka, Janice A; Staverosky, Julia A; Reddy, Ashok P et al. (2018) Biomechanical Rigidity and Quantitative Proteomics Analysis of Segmental Regions of the Trabecular Meshwork at Physiologic and Elevated Pressures. Invest Ophthalmol Vis Sci 59:246-259
Lane, Ryan S; Lund, Amanda W (2018) Non-hematopoietic Control of Peripheral Tissue T Cell Responses: Implications for Solid Tumors. Front Immunol 9:2662
Tyner, Jeffrey W; Tognon, Cristina E; Bottomly, Daniel et al. (2018) Functional genomic landscape of acute myeloid leukaemia. Nature 562:526-531
Risom, Tyler; Langer, Ellen M; Chapman, Margaret P et al. (2018) Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer. Nat Commun 9:3815
Minnier, Jessica; Pennock, Nathan D; Guo, Qiuchen et al. (2018) RNA-Seq and Expression Arrays: Selection Guidelines for Genome-Wide Expression Profiling. Methods Mol Biol 1783:7-33
Su, Yulong; Pelz, Carl; Huang, Tao et al. (2018) Post-translational modification localizes MYC to the nuclear pore basket to regulate a subset of target genes involved in cellular responses to environmental signals. Genes Dev 32:1398-1419
Gast, Charles E; Silk, Alain D; Zarour, Luai et al. (2018) Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival. Sci Adv 4:eaat7828
Krey, Jocelyn F; Scheffer, Deborah I; Choi, Dongseok et al. (2018) Mass spectrometry quantitation of proteins from small pools of developing auditory and vestibular cells. Sci Data 5:180128
Rozanov, Dmitri V; Rozanov, Nikita D; Chiotti, Kami E et al. (2018) MHC class I loaded ligands from breast cancer cell lines: A potential HLA-I-typed antigen collection. J Proteomics 176:13-23

Showing the most recent 10 out of 277 publications